文献速递前列腺癌

转移性前列腺癌嵌合抗原受体T细胞治疗的挑战与前景

Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-08-28

本文综述了CAR T细胞治疗转移性前列腺癌的临床结果与技术瓶颈。迄今CAR T细胞疗法在转移性前列腺癌患者中未显示显著活性,原因为CAR设计和细胞组成欠佳。提出通过无偏识别新靶点、使用下一代CAR产品及联合治疗可能改善疗效。

要点

  • 现有CAR T细胞疗法在转移性去势抵抗性前列腺癌中未显示显著活性。
  • 需优化CAR设计以在 hostile 肿瘤微环境中提供强效活性和持久性。
  • 联合治疗及下一代多特异性CAR产品有望提高疗效。

核心结论

  • 现有CAR T细胞疗法在转移性前列腺癌患者中未显示显著活性。
  • 需通过改进CAR设计和患者预处理策略来提升疗效。

研究设计与样本

  • 文献综述,涵盖临床试验数据、近期肿瘤学会议摘要及临床前和临床研究报告。

主要发现

  • CAR T细胞疗法在血液系统B细胞恶性肿瘤中成功,但在晚期前列腺癌中疗效有限。
  • CAR设计需提供强效活性和持久性以应对 hostile 肿瘤微环境。
  • 靶向表位选择对抵消肿瘤抗原逃逸至关重要。
  • 临床前和临床证据表明联合其他治疗可显著增强CAR T细胞疗效。

关键数值与推荐

  • 推荐无偏识别新的前列腺癌特异性CAR靶点。
  • 推荐使用下一代多特异性、抗肿瘤微环境且持久性延长的CAR T细胞产品。
  • 推荐联合治疗策略。

临床怎么用

  • 临床医生应与细胞生物学家对话,共同解决CAR T细胞治疗前列腺癌的挑战。
  • 关注下一代CAR T细胞产品的临床试验,其预期在临床中更成功。

局限性

  • 现有临床试验中使用的CAR T细胞产品设计和细胞组成可能欠佳,难以预期强效患者反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Progress achieved in the treatment of prostate cancer (PCa) with surgical, radiation, and hormonal therapies has drastically reduced mortality from this disease. Yet, patients with advanced PCa have few, if any, curative options. Recent success in treating patients with hematological malignancies of B-cell origin using T cells engineered to express chimeric antigen receptors (CARs) has inspired multiple groups worldwide to adapt this approach to the problem of late-stage PCa. OBJECTIVE: To summarize the available clinical results for CAR T-cell therapy of PCa and discuss future technological advancements in the CAR T-cell field that may help patients with metastatic PCa. EVIDENCE ACQUISITION: A literature review was conducted of clinical trial data, abstracts presented at recent oncology conferences, as well as reports highlighting critical bottlenecks of CAR T-cell therapy that became apparent from preclinical and clinical studies. EVIDENCE SYNTHESIS: Current understanding of why CAR T-cell therapy may fail, particularly in the context of solid cancers, is as follows. First, a CAR design that provides potent activity and persistence of engineered T cells in the hostile tumor microenvironment is a must. The choice of the targetable epitope(s) is critical to counteract tumor antigen escape. Preclinical and clinical evidence indicates that the efficacy of CAR T-cell therapy can be enhanced significantly in combination with other therapeutic approaches. We propose that several improvements to CAR design and patient conditioning, such as unbiased identification of novel PCa-specific CAR targets, use of next-generation (multispecific, resistant to the tumor microenvironment, and with prolonged persistence) CAR T-cell products, and combination therapies may translate into improved patient outcomes and more durable responses. CONCLUSIONS: Although significant preclinical experience of testing CAR T cells in solid cancer models has identified important technological and biological bottlenecks, information from clinical trials, particularly those focusing on the PCa, will be instrumental to the rational design of advanced CAR T therapies that will be both safe and effective in patients with advanced PCa. PATIENT SUMMARY: So far, chimeric antigen receptor (CAR) T-cell therapy has not shown significant activity in patients with metastatic prostate cancer (PCa). CAR T-cell products used for such trials represent one of the pioneering efforts to adapt this technology to the problem of metastatic PCa. In retrospect, both CAR design and cell composition appear to have been suboptimal to expect strong patient responses. Given the impressive results of CAR-based approaches observed in preclinical models of solid cancers, emerging CAR T-cell products are expected to be more successful in the clinic. Here, we discuss the challenges that need to be overcome to boost the efficacy of PCa-targeted CAR T-cell therapy and call for dialogue between clinicians and cell biologists to address these challenges.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gorchakov AA, Kulemzin SV, Kochneva GV, et al. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. Eur Urol. 2019. PMID: 31471138. doi:10.1016/j.eururo.2019.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。